Taj Pharma Bags USFDA Nod For Colistimethate sodium injection

Indian pharmaceuticals group announced USFDA approval for Colistimethate sodium for injection and inhalation for
United States market.
Mumbai, Maharashtra, March 10, 2012 /India PRwire/ -- Taj Pharma Group declared that it has bagged nod from
USFDA to sell Colistimethate sodium for injection and inhalation in the United States. Each Injection contains
Colistin 1 MIU - 1 Million International Units (1 MIU) Colistimethate Sodium.
In an interview with CNBC, Group CEO A.K.Singh said, 'the proposed U.S. launch will be very affordable for US
citizens facing specific lung infections, the generics Colistimethate will be available at very reasonable prices
benefitting the American hospitals'.
The company will sell Colistin 1 MIU is available in vial of 10 ml in Powder for solution for injection, infusion and
inhalation.
Colistimethate sodium powder for inhalation (Colobreathe) for Pseudomonas aeruginosa lung infection in cystic
fibrosis.
Inhalation may induce coughing or bronchospasm. Sore throat or mouth has been reported and may be due to
Candida albicans infection or hypersensitivity. Skin rash may also indicate hypersensitivity; if this occurs, treatment
should be withdrawn.
Colistin is contraindicated in patients with known hypersensitivity to colistimethate sodium (colistin) or to polymyxin
B and in patients with myasthenia gravis.
Colistimethate sodium is a cyclic polypeptide antibiotic derived from Bacillus polymyxa var. colistinus and belongs
to the polymyxin group. The polymyxin antibiotics are cationic surface-active agents that work by damaging the cell
membrane. The resulting physiological effects are lethal to the bacterium. Polymyxins are selective for
Gramnegative bacteria that have a hydrophobic outer membrane.
Notes to Editor
About Taj Pharma India
Taj Pharmaceuticals Limited is known as a pharmaceuticals manufacturing company found and based in India. The
company manufacturer's pharmaceuticals formulations and API for India and other countries. The company was
established in 1995 as an enterprise and in 2004 became a public limited company. As per Mumbai pharmaxil and
Chemixil association the company manufacturers and exports to countries like Iran, Iraq and Asia Pacific. In recent
EU-Indonesia Business Dialogue (EIBD) conference Taj Pharma Group was listed amongst top 10 pharmaceutical
companies in EU by 2008 sales. The Group sales 16,234 ($M) making the company 12 ranked in EU by 2008
sales. Founded as a company for finished formulation marketing and Export and then entered Api and Agro
business in 2004 and 2007 respectively.
About Network18
Network18 Media & Investments Limited (BSE: 532798, NSE: Network18) is an Indian media conglomerate with
interests in television, print, internet, film, mobile content and allied businesses. Network 18 FinCap is the holding
company for several media entities in India such as Television Eighteen India Ltd (TV18), IBN 18 Broadcast Ltd,
Web 18, Studio 18,Shop 18,Infomedia 18 and Viacom 18. Raghav Bahl holds 51% shares of Network 18 Group.
The group includes Network18, TV18, ibn18 and Infomedia18, all of which are listed in India on NSE & BSE. The
company is owned by Raghav Bahl who has 51% stake in Network 18.
For more information, please contact:
Vandana Malik
Executive Director

page 1 / 2

(L) +91-22-6666 7777, (F) +91-22-2496 8238

copyright 2016 India PRwire (http://www.indiaprwire.com)

India PRwire disclaims any content contained in press release. Use of our service is governed by our privacy policy and terms of service.

page 2 / 2